Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470131 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
A Phase 3 study, sponsored by AB Science.
- Terminated
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT01470131: Clinical Trial Phase 3 study, sponsored by AB Science.
NCT01470131 is a Phase 3 study that was terminated before completion, run by AB Science. The registered enrollment target is 147 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01470131, a Phase 3 study, was terminated before completion, sponsored by AB Science.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients with relapsing multiple myeloma who have received one previous therapy.
Interventions
- DRUG Placebo
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG Masitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2011-05 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 3 |
Why NCT01470131 stopped before completion
NCT01470131 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01470131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01470131 about?
NCT01470131 is a clinical study titled "A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma". The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients with relapsing multiple myeloma who have received one previous therapy.
What is the current status of trial NCT01470131?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2011-05. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT01470131?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG), Bortezomib (DRUG), Masitinib (DRUG).
Who is sponsoring clinical trial NCT01470131?
This trial is sponsored by AB Science, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01470131's enrollment target sits among peer trials
147 1550th of 2000 higher than 450 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia